Abstract
Resolution of clinical signs, a complete response, and long-term survival (> 23 Years) in a 3 and ½ month female with a newly diagnosed diffuse intrinsic pontine glioma treated with antineoplastons
Highlights
Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumor–related death in children
ANP is an effective treatment for DIPG and for a variety of low- and high-grade brain tumors
Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, but without success
Summary
Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumor–related death in children. Over the past few decades, clinical trials have shown no improvement in outcome The purpose of this correspondence is to discuss the use of IV and oral Antineoplaston therapy (ANP {A10 + AS2-1}) in the treatment of a 3 and 1⁄2 month female with newly-diagnosed DIPG. Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric tumor with a median age at diagnosis of 6–7 years. Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, but without success. The median survival for children with DIPG is less than one year from diagnosis and no improvement in survival has been realized in more than three decades [2,3]. Classic findings on clinical examination include the triad of multiple cranial neuropathies, long tract signs (hyperreflexia, clonus, increased tone, presence of a Babinski reflex), and ataxia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
